caa a22 4500 469120193 CHVBK 20180323133136.0 cr unu---uuuuu 170328e19920501xx s 000 0 eng 10.1007/BF02244970 doi (NATIONALLICENCE)springer-10.1007/BF02244970 Comparison of the daytime sleep and performance effects of zolpidem versus triazolam [Elektronische Daten] [Thomas Balkin, Vincent O'Donnell, Nancy Wesensten, Una McCann, Gregory Belenky] Fifty healthy male subjects were administered zolpidem (5, 10, or 20 mg), triazolam (0.5 mg) or placebo, then attempted to sleep in a non-sleep-conductive environment. Subjects were awakened at 90 min post-drug (near peak blood concentration for both drugs) and tested on several cognitive tasks, including Two Column Addition, Logical Reasoning, and a Simulated Escape Task. This was followed by a second, 3.5-h sleep period. Hypnotic efficacy of the 20 mg zolpidem (Z-20) dose was similar to that of the 0.5 mg triazolam (TRIAZ) dose, as indicated by comparably shortened sleep latencies and lengthened total sleep times. Though accuracy on most performance measures was not affected by either drug, a reduction in speed of responding on logical reasoning and addition tasks was evident for the TRIAZ group at 90 min post-drug (Ps<0.05). On the simulated escape task, only triazolam significantly increased the mean number of errors, and interfered with subsequent memory of the task. Thus, zolpidem had milder effects on performance than triazolam. However, 60% of the Z-20 subjects experienced mild, adverse physical reactions. Performance differences between somnogenically comparable doses of zolpidem and triazolam may be due to their differential affinities for the BZ1 and BZ2 receptor subtypes. Springer-Verlag, 1992 Zolpidem nationallicence Triazolam nationallicence Cognitive performance nationallicence Sleep nationallicence Memory nationallicence Balkin Thomas Human Psychopharmacology Branch, Department of Behavioral Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC, USA aut O'Donnell Vincent Human Psychopharmacology Branch, Department of Behavioral Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC, USA aut Wesensten Nancy Human Psychopharmacology Branch, Department of Behavioral Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC, USA aut McCann Una Human Psychopharmacology Branch, Department of Behavioral Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC, USA aut Belenky Gregory Human Psychopharmacology Branch, Department of Behavioral Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC, USA aut Psychopharmacology Springer-Verlag 107/1(1992-05-01), 83-88 0033-3158 107:1<83 1992 107 213 https://doi.org/10.1007/BF02244970 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02244970 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Balkin Thomas Human Psychopharmacology Branch, Department of Behavioral Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC, USA aut NATIONALLICENCE 700 1- O'Donnell Vincent Human Psychopharmacology Branch, Department of Behavioral Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC, USA aut NATIONALLICENCE 700 1- Wesensten Nancy Human Psychopharmacology Branch, Department of Behavioral Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC, USA aut NATIONALLICENCE 700 1- McCann Una Human Psychopharmacology Branch, Department of Behavioral Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC, USA aut NATIONALLICENCE 700 1- Belenky Gregory Human Psychopharmacology Branch, Department of Behavioral Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC, USA aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 107/1(1992-05-01), 83-88 0033-3158 107:1<83 1992 107 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer